1,467 results on '"Distler O"'
Search Results
2. Low back pain patients with Modic type 1 changes exhibit distinct bacterial and non-bacterial subtypes
3. OP0192 SYNOVITIS IN SYSTEMIC SCLEROSIS IS CHARACTERISED BY AN INTERFERON SIGNATURE
4. AB1199 PATIENTS AND PHYSICIANS ATTRIBUTE IMPORTANCE DIFFERENTLY WHEN CONSIDERING OUTCOMES AND SEVERITY OF INTERSTITIAL LUNG DISEASE ASSOCIATED TO SYSTEMIC SCLEROSIS: RESULTS OF AN INTERNATIONAL SURVEY
5. AB1176 SCOPING REVIEW TO GUIDE THE DEVELOPMENT OF AN ARTICULAR SCORE IN SYSTEMIC SCLEROSIS (ASSESS SCORE)
6. POS0204 EFFECTIVENESS OF TNF INHIBITION IN VERY EARLY AXIAL SPONDYLOARTHRITIS (LESS THAN ONE YEAR OF AXIAL SYMPTOM DURATION): RESULTS FROM A LARGE NATIONAL OBSERVATIONAL COHORT
7. OP0256 EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION ON FREQUENCY OF FECAL INCONTINENCE SYMPTOMS IN SYSTEMIC SCLEROSIS PATIENTS WITH MODERATE TO SEVERE LOWER GASTROINTESTINAL DISEASE
8. POS0343 HIGHER ABUNDANCE OF HTRA1 GENERATED FRAGMENTS IN THE DEGRADOME OF MODIC TYPE 1 DISCS
9. POS0838 SELECTIVE HRCT SCREENING IN AT-RISK SYSTEMIC SCLEROSIS PATIENTS REVEALS SUBSTANTIAL UNDERDIAGNOSIS OF INTERSTITIAL LUNG DISEASE
10. POS0235 NEW ONSET OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: CLINICAL COURSE AND OUTCOMES FROM A EUSTAR DATABASE ANALYSIS
11. POS0211 PAH TREATMENT AT TIME OF DIAGNOSIS IS ASSOCIATED WITH IMPROVED SURVIVAL REGARDLESS OF HEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION - A EUSTAR ANALYSIS
12. POS0230 CHARACTERISTICS AND DISEASE COURSE OF SSc-ILD PATIENTS WITH GASTROESOPHAGEAL REFLUX – AN ANALYSIS OF THE EUSTAR COHORT
13. POS0832 IMMUNOSUPPRESSION VERSUS COMBINATION OF IMMUNOSUPPRESSION AND ORAL GLUCOCORTICOIDS FOR SKIN FIBROSIS IN EARLY DIFFUSE SYSTEMIC SCLEROSIS PATIENTS. A TARGET TRIAL EMULATION STUDY FROM THE EUSTAR DATABASE
14. OP0068 INTERSTITIAL LUNG DISEASE IS FREQUENTLY PROGRESSIVE IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
15. POS0259 DOES BIOLOGIC DMARD RETENTION IN AXIAL PSORIATIC ARTHRITIS DEPEND ON THE MODE OF ACTION? COMPARISON OF TNF, IL-17, AND IL-23 INHIBITORS IN A LARGE OBSERVATION COHORT
16. POS0225 PROGNOSTIC VALUE OF CHANGE IN FORCED VITAL CAPACITY (FVC) AT WEEK 12 OR 24 IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES (ILDs)
17. OP0056 DECIPHERING THE CROSSTALK BETWEEN CD74+ SYNOVIAL FIBROBLASTS AND IMMUNE CELLS IN RHEUMATOID ARTHRITIS
18. POS0559 DISCOVERING BLOOD-BASED BIOMARKERS FOR SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION
19. POS0196 DISEASE BURDEN AND IMPACT OF FECAL INCONTINENCE IN SYSTEMIC SCLEROSIS - DATA FROM THE RANDOMIZED ReSScue TRIAL
20. POS1201 CHI3L1 AND CHI3L2 REPRESENT TWO HIGHLY SPECIFIC SYNOVIAL FIBROBLAST-RELATED BIOMARKERS IN SEROPOSITIVE AND –NEGATIVE RHEUMATOID ARTHRITIS
21. OP0034 DIFFERENTIAL JOINT-LEVEL RESPONSES TO TNF INHIBITORS IN PSORIATIC ARTHRITIS: A COLLABORATIVE EUROPEAN OBSERVATIONAL COHORT STUDY
22. OP0013 ANTI-Ro/SSA ANTIBODIES ARE PREDICTIVE OF A MORE SEVERE LUNG INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR HDATABASE
23. AB1145 DECIPHERING THE SPATIAL HETEROGENEITY OF SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE BY INTEGRATIVE RADIOMICS AND SINGLE-NUCLEUS TRANSCRIPTOMIC PROFILING
24. POS0432 DRIVERS OF DISEASE BURDEN IN PATIENTS WITH SYSTEMIC SCLEROSIS ACROSS CLINICAL AND DEMOGRAPHIC SUBGROUPS REVEALED BY THE EULAR SYSTEMIC SCLEROSIS IMPACT OF DISEASE (ScleroID) QUESTIONNAIRE
25. Traitement continu par nintedanib chez des patients présentant une pneumopathie interstitielle diffuse associée à la sclérodermie systémique (PID-ScS) : données à trois ans de SENSCIS-ON
26. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research
27. Eine seltene Differenzialdiagnose von „atraumatischen“ Schulterschmerzen
28. Systemische Sklerose – klinisches Bild, Diagnostik und Therapie
29. Therapiestrategien bei systemischen Vaskulitiden
30. Formen der Vaskulitis
31. Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
32. Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials
33. OP0098 INFLAMMATORY GENE ENHANCERS ARE SHARED IN SYNOVIAL FIBROBLASTS AND MINOR SALIVARY GLAND FIBROBLASTS
34. POS1275 THE HETEROGENEITY OF DEFINING SEVERITY, PROGRESSION AND OUTCOMES IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW
35. OP0064 OBESITY IN PSORIATIC ARTHRITIS IS INCREASINGLY AFFECTING MEN AND APPEARS LESS DEPENDENT OF SOCIOECONOMIC STATUS THAN IN THE GENERAL POPULATION
36. POS0618 QUANTITATIVE RADIOMIC RISK SCORE STRATIFIES RESPONSE TO ANTI-FIBROTIC TREATMENT IN A PRECLINICAL LUNG FIBROSIS MODEL
37. POS0626 PERTURBED LIPID METABOLISM IS A CENTRAL METABOLIC REPROGRAMMING HUB IN SYSTEMIC SCLEROSIS
38. OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS
39. POS1216 MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: DATA FROM A LARGE, GLOBAL E-SURVEY (COVAD STUDY)
40. AB0877 TARGETING VASCULOPATHY TO SLOW FIBROSIS IN SYSTEMIC SCLEROSIS (SSC): DESIGN OF A PHASE II STUDY WITH A SOLUBLE GUANYLATE CYCLASE ACTIVATOR (SGCA)
41. AB1394 INTRADISCAL CUTIBACTERIUM ACNES DECIDE ON INNATE AND ADAPTIVE IMMUNE PATHWAYS IN MODIC TYPE 1 CHANGES
42. POS0573 COMORBIDITIES, COMPLEX MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES AMONGAUTOIMMUNE RHEUMATIC DISEASES: DATA FROM THE COVAD STUDY
43. POS0273 POST COVID-19 SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVAD STUDY
44. POS1215 FLARES AFTER COVID-19 INFECTION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: RESULTS FROM THE COVAD STUDY
45. POS0417 ACTIVATED NEUTROPHILS DEGRADE CARTILAGE ENDPLATES
46. OP0234 2023 UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS
47. POS0256 IDENTIFICATION OF TWO BIOLOGICAL SUBTYPES OF CRPS
48. POS1310 FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND LOWER GASTROINTESTINAL TRACT SYMPTOMS: DATA FROM THE RESSCUE RANDOMIZED CLINICAL TRIAL
49. POS0269 COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN SJÖGREN’S SYNDROME: RESULTS FROM THE COVAD STUDY
50. POS1258 RESULTS FROM A NOMINAL GROUP TECHNIQUE EXERCISE FOR THE CREATION OF A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: THE CRISTAL PROJECT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.